Ancillary Studies

Ancillary Studies Overview

A B2B Program ancillary study is any investigation that uses B2B Program resources, including existing data or biological specimens, or the collection of new data or specimens from participants, and is supported by funding other than the core B2B CHANGE award.

External funding may include investigator-initiated NIH research awards (e.g., R01 or P01 awards), foundation grants, or private or industry sources.

Who Can Participate?

Investigators across the congenital heart disease community, including current and previously funded investigators as well as researchers new to the field, are encouraged to propose and conduct ancillary studies that advance the science of CHD and related disorders.

Such studies enhance the value of the B2B Program, promote expanded involvement of investigator teams, and advance our understanding of the causes, mechanisms, and outcomes of CHD.

Application Requirements

An application is required for all ancillary studies and allows the Program to ensure alignment with the main protocol, avoid scientific overlap, and track the use and scientific impact of CHANGE data/specimens.

Application Materials

Ancillary Study Policy: Pending

Application Form: Pending (REDCap Form)

Review and Approval

The B2B CHANGE Ancillary Study Committee will review requests. The B2B CHANGE Data Coordinating Center (DCC) will notify the requestor of the committee’s decision to approve the request.

If approved, external investigators must agree to:

  • Appropriately acknowledge B2B CHANGE in publications involving B2B CHANGE patients/data.
  • Include B2B CHANGE collaborators as authors on publications when contributions engage in sufficient activities to warrant authorship.

The DCC will provide the external investigator with an acknowledgement statement template that includes grant numbers to be inserted into publications.

If a request is not approved, the DCC will notify the investigator by email with an explanation for why it was not approved and any recommendations for a subsequent resubmission.

Active Ancillary Studies

Project TitleSpecific AimsPI Name

P01

Aim 1: To deepen our understanding of the genetic causality of CHD. Half of CHD causality is currently unknown.

Aim 2: To uncover drivers of variability in cardiac and non-cardiac outcomes among individuals with CHD.

Aim 3: To gain mechanistic insights into the roles of genetic variation in altering cell composition and gene expression in CHD cardiac tissues.

Bruce Gelb, MD
Project 1 CHD Causality 

Aim 1: Find novel CHD genes through new approaches for analyzing existing and previously unanalyzed PCGC ES and srGS data.

Aim 2: Determine the contribution of structural variants (SVs) and DNA methylation to CHD pathogenesis.

Aim 3: Increase the size of the genomic dataset to allow detection of ultra-rare coding and non-coding variation causing CHD.

Bruce Gelb, MD
Project 2 CHD Outcomes

Aim 1: Learn stable multimodal representations to surface the most influential variable sets for CHD outcomes.

Aim 2: Validate and disseminate explainable AI-based machinery integrating clinical, phenotypic, SDOH and genomic variables for predicting adverse clinical outcomes in CHD.

Aim 3: Define novel genetic conditions associated with CHD and characterize their phenotypic spectrum.

Marti Tristani, MD
Project 3 Gene Expression in CHD

Aim 1: Identify and characterize cell types and states in pNFC and CHD hearts using snRNAseq and identify novel QTLs.

Aim 2: Characterize and compare pNFC and CHD hearts from newborn to adult using CaMVIA-3D, RNAscope, and spatial transcriptomics.

Aim 3: Define shared and distinct gene programs operant in CHD and assess their association and eQTLs with clinical phenotypes and outcomes.

Christine Seidman, MD
Project 4 Determinants of Neurologic Outcomes in CHD

Aim 1: Identify genetic factors that contribute to MRI-derived brain structure in persons with CHD.

Aim 2: Quantify the contribution of genomic variation to NDD risk in persons with CHD.

Aim 3: Develop an integrated, multimodal model to stratify NDD risk and elucidate pathogenic mechanisms.

Sarah Morton, MD
Core Computational Core

Aim 1: Benchmark, optimize, and develop computational methods for predicting genetic effect of missense variants.

Aim 2: Benchmark, optimize, and develop computational methods for predicting genetic effect of non-coding variants.

Aim 3: Support cross-project integration.

Yufeng Shen, PhD
Maternal Genetic Risk Factors for CHD

Aim 1: Identify genes that act through the case genotype (after accounting for the maternal genotype) to influence the risk of all CHD, followed by subgroup analyses for CTD and LVOTO.

Aim 2: Identify genes that act through the maternal genotype to influence the risk of all CHD, followed by subgroup analyses for CTD and LVOTO.

AJ Agopian, PhD
Association between maternal factors and preterm birth/small for gestational age among infants with congenital heart defects

Aim 1: Identify maternal, paternal, and infant non-genetic risk factors for preterm birth and SGA among infants with CHDs.

Aim 2: Identify maternal and infant genetic risk factors for preterm birth and SGA among infants with CHDs.

AJ Agopian, PhD
Genetic Consequences of Consanguinity in CHD

Aim 1: To test the hypothesis that consanguinity potentially defines a subtype of CHD.

Aim 2: To understand the genetic consequences and molecular dynamics of CHD in patients who arise from consanguinity.

Bakhrom Berdiev, MD, PhD
Origins and Burden of Multi-Organ Fibrosis in Patients with Single Ventricle Heart DiseaseAim 1: Explore the association of genetic variants within candidate pathways regulating fibrogenesis with myocardial fibrotic load on CMR in patients with SVD.Betsy Goldmuntz, MD
Genetics of non-syndromic conotruncal defects

Aim 1: Define gene sets that influence the risk of CTRDs via common inherited genetic variants across the genome.

Aim 2: Define gene sets that influence the risk of CTRDs via rare genetic variants across the exome.

Aim 3: Establish the genetic basis of the CTRD phenotypic spectrum.

Betsy Goldmuntz, MD
Locking and Unlocking Cardiac Maturation

Aim 1: Establish a functional human cardiomyocyte ERR enhancer-promoter catalog.

Aim 2: Use the ERR enhancer-promoter element catalog to identify rare and common ERR binding site variants in CHD probands in the PCGC database.

Daniel Kelly, MD
Identification of gene-dosage imbalances causing Congenital Heart Disease

Aim 1: Assemble the most complete dataset of gene-copy variants using multiple public data sources and those acquired through collaboration.

Aim 2: Curate the data in order to get high-quality sets for individuals without congenital diseases and individuals with congenital heart defects.

Aim 3: Divide the genomic data into sets of functionally-related genes.

Aim 4: Analyse the genetic data in order to identify gene-copy imbalances linked to CHD.

David Talavera, MD
Status of Prenatal Screening for Congenital Heart Disease

Aim 1: What are the rates of prenatal diagnosis among infants with a variety of congenital heart defects among the CHD GENES cohort of infants ≤ 1 year old at the time of consent?

Aim 2: What is the correlation between the type of prenatal screening and the rate of prenatal diagnosis for congenital heart disease?

Aim 3: Is there a correlation between the mother’s ethnicity and age and the rate of prenatal testing?

Aim 4: Is there a correlation between the presence of extracardiac defects and/or genetic conditions and the rate of prenatal screening?

Dorota Gruber, PhD
Genotype-phenotype study ARID1A

Aim 1: Are missense mutations in ARID1A pathogenic? If so, is it possible to determine the characteristics of these mutations, such as whether the mutations occur in specific protein domains?

Aim 2: Are mutations mosaic or not?

Aim 3: Do all patients with ARID1A mutations have a Coffin-Siris phenotype?

Aim 4: Is there a correlation between the degree of mosaicism and the severity of the phenotype, as defined by the number of congenital anomalies?

Gijs WE Santen, MD, PhD
Eline van der Sluijs, MD/PhD student
Clonal Hematopoiesis as a Mechanistic Link Between Congenital Heart Defects and Cancer Risk in Pediatric Populations

Aim 1: Implement computational methods to identify and characterize clonal hematopoiesis in the PCGC and SSC cohorts.

Aim 2: Investigate the relationship between clonal hematopoiesis and CHD in cancer-associated genes.

Jing Chen, PhD
The Association of Damaging Genetic Variation With Ventricular Function in Hypoplastic Left Heart Syndrome

Aim 1: Identify deleterious de novo and inherited mutations, including damaging CNVs, in a cohort of patients with hypoplastic left heart syndrome recruited from the PHN and PCGC.

Aim 2: Collect pertinent clinical data on a multicenter cohort of HLHS from the PHN and PCGC and test the association of damaging genetic variation with echocardiographic and cardiac magnetic resonance metrics of ventricular function as defined by a core cardiac imaging laboratory.

Matt Lewis, MD
Random field method for mapping molecular QTLs and discovering molecular pathways contributing to CHD risk

Aim 1: Apply a recently developed random field method for mapping molecular quantitative trait loci.

Aim 2: Use bi-dimensional Mendelian Randomization to nominate molecular pathways underlying CHD development.

Ming Li, PhD
Amendment to Genetic diagnoses among a cohort of children with pulmonary stenosis

Aim 1: Describe incidence and spectrum of monogenic disorders among 450 probands with pulmonary stenosis.

Aim 2: Characterize extracardiac phenotypes in a cohort of 450 probands with pulmonary stenosis.

Aim 3: Identify at least one candidate gene for syndromic pulmonary stenosis.

Nicole Weaver, MD
Histone-3 Lysine-4 Methylation and OligodendrocytesAim 1: Determine if restoration of normal H3K4me can prevent/rescue deficits in OL development.Nobuyuki Ishibashi, MD
Combinatorial effects of neonatal anesthesia and primary cilia deficits on neurobehavior outcomes in CHD

Aim 1: To define the characteristics of primary cilia deficiency in human iPSC-derived neurons with mutations of genes associated with congenital heart disease.

Aim 2: To define the effects of primary cilia deficiency on anesthesia-induced neurodegeneration in human iPSC-derived neurons with mutations of genes associated with congenital heart disease.

Aim 3: To characterize human iPSC-derived neurons with the CHD7 mutation and determine the effects of the mutation on anesthesia-induced neurodegeneration in human iPSC-derived neurons.

Nobuyuki Ishibashi, MD
Kazue Hashimoto-Torii, PhD
Exploring Genetic Pleiotropy Between Congenital Heart Disease and HydrocephalusAim 1: Identify genetic etiologies underlying pleiotropic effects on congenital heart disease and congenital hydrocephalus.Sheng Chih Jin, PhD
A One-Platform Long-Read Sequencing Resource for Prader-Willi Syndrome with Congenital Heart Disease

Aim 1: Identify genetic and epigenetic contributors to congenital heart defects in Prader-Willi Syndrome using advanced long-read sequencing.

Aim 2: Create an integrated, PWS-focused genomic resource to support research and data sharing.

Sheng Chih Jin, PhD
Conotruncal Heart Defects and Variants in Folate Metabolism GenesAim 1: Utilize genomic data available through the NCBI Database of Genotypes and Phenotypes (dbGaP) involving patients with CTHD and a healthy, unaffected population to perform a case-control association study in candidate genes in folate metabolism comparing groups before and after folic acid fortification.Tina Oak Findley, MD
Regulatory genetic variants in congenital heart disease risk

Aim 1: Regulatory variants as potential modifiers of coding CHD risk variants.

Aim 2: Novel methods development to identify rare regulatory variants.

Tuuli Lappalainen, PhD

Small Data Requests

B2B CHANGE considers a request for phenotype data as limited if it meets the following criteria:

  • Patient re-contact is not required,
  • Data are limited to 10 or fewer patients when data already exist in HeartsMart, or
  • Data are limited to 5 or fewer patients when data exist in the medical record.

To streamline the process for obtaining these data from the PCGC, investigators should submit a limited data request form (Pending REDCap Form).

Requests should include a short description of the project, the type of information requested, and the number of patients involved in the request.

If you need assistance getting connected with a B2B CHANGE principal investigator, please contact the DCC.